Bipolar Disorder - Canada Drug Forecast and Market Analysis to 2024 Summary Bipolar disorder is a mental disorder characterized by periods of mania and depression. The frequency, severity, and pattern of these episodes can vary considerably over time and between individuals, making bipolar disorder one of the most challenging psychiatric disorders to manage. The bipolar disorder market is widely genericized, with additional key brands expected to face patent or data exclusivity expiries during the forecast period. The bipolar disorder market size is anticipated to contract significantly between 2014 and 2024, driven largely by the generic erosion of Otsuka's Abilify, the highest selling bipolar disorder product in 2014. The uptake of novel atypical antipsychotic products will be a principal driver of growth over the forecast period, as these products offer clinical advantages that will drive strong uptake. However, sales of these agents will be limited by the continued utilization of established generic products. There are currently only two products in Phase III development, which indicates that bipolar disorder will remain a field of high unmet need during the forecast period. GlobalData estimates the value of the Canadian bipolar disorder market to have been approximately $167.8m in 2014. Canada's market size is limited by the country's low population. Drug sales in this country are expected to stay largely constant over the forecast period, as represented by the flat CAGR. Sales are then expected to decline between 2017 and 2023 due to the generic erosion of various brands including Otsuka's Abilify, Pfizer's Zeldox, Allergan's Saphris, and Janssen's Risperdal Consta. *This is an on-demand report and will be delivered within 24 hrs. (excluding weekends) of the purchase. Scope - Overview of Bipolar Disorder including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape. - Detailed information on the key drugs in Canada including product description, safety and efficacy profiles as well as a SWOT analysis. - Sales forecast for the top drugs in Canada from 2014-2024. - Analysis of the impact of key events as well the drivers and restraints affecting Canada Bipolar Disorder market. Reasons To Buy - Understand and capitalize by identifying products that are most likely to ensure a robust return - Stay ahead of the competition by understanding the changing competitive landscape for Bipolar Disorder. - Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential - Make more informed business decisions from insightful and in-depth analysis of drug performance - Obtain sales forecast for drugs from 2014-2024 in Canada.
Table of Contents
1.1 List of Tables 1.2 List of Figures 2 Introduction 2.1 Catalyst 2.2 Related Reports 2.3 Upcoming Related Reports 3 Disease Overview 3.1 Etiology and Pathophysiology 3.1.1 Etiology 3.1.2 Pathophysiology 3.2 Classification 3.3 Symptoms 3.4 Prognosis 4 Disease Management 4.1 Diagnosis Overview 4.1.1 Clinical Evaluation 4.1.2 Screening Tools 4.2 Treatment Overview 4.2.1 Treatment Initiation and Maintenance Therapy 4.2.2 Manic or Mixed Episodes 4.2.3 Acute Agitation 4.2.4 Hypomanic Episodes 4.2.5 Major Depressive Episodes 4.2.6 Rapid Cycling 4.2.7 Cyclothymia 4.2.8 Other Treatment Factors 4.3 Treatment Guidelines and Leading Prescribed Drugs 4.4 Canada 5 Competitive Assessment 5.1 Overview 5.2 Product Profiles - Major Brands 5.2.1 Lithium 5.2.2 Anticonvulsants 5.2.3 Typical Antipsychotics 5.2.4 Atypical Antipsychotics 5.2.5 Antidepressants 5.3 Other Therapeutic Classes 6 Unmet Need and Opportunity 6.1 Overview 6.2 Effective Treatment Options for Bipolar Depression 6.2.1 Unmet Need 6.2.2 Gap Analysis 6.2.3 Opportunity 6.3 Antipsychotics with a Low Risk of EPS and Metabolic Changes 6.3.1 Unmet Need 6.3.2 Gap Analysis 6.3.3 Opportunity 6.4 Mood Stabilizers with Improved Safety Profiles 6.4.1 Unmet Need 6.4.2 Gap Analysis 6.4.3 Opportunity 6.5 Education for Physicians in Order to Improve Diagnosis Rates 6.5.1 Unmet Need 6.5.2 Gap Analysis 6.5.3 Opportunity 6.6 Novel Drugs Developed Specifically for Bipolar Disorder 6.6.1 Unmet Need 6.6.2 Gap Analysis 6.6.3 Opportunity 7 Pipeline Assessment 7.1 Overview 7.1.1 Clinical Trials by Class of Therapy 7.2 Promising Drugs in Clinical Development 7.2.1 Abilify Maintena 7.2.2 ITI-007 7.3 Off-label Pipeline and Recently Approved Therapies 7.4 Promising Drugs in Early-Stage Development 7.5 Other Drugs in Development 8 Market Outlook 8.1 Canada 8.1.1 Forecast 8.1.2 Key Events 8.1.3 Drivers and Barriers 9 Appendix 9.1 Bibliography 9.2 Abbreviations 9.3 Methodology 9.4 Forecasting Methodology 9.4.1 Diagnosed Bipolar Disorder Patients 9.4.2 Percent Drug-Treated Patients 9.4.3 Launch and Patent Expiry Dates 9.4.4 General Pricing Assumptions 9.4.5 Individual Drug Assumptions 9.4.6 Generic Erosion 9.5 Primary Research - KOLs Interviewed for this Report 9.6 Primary Research - Prescriber Survey 9.7 About the Authors 9.7.1 Analyst 9.7.2 Therapy Area Director 9.7.3 Epidemiologist 9.7.4 Global Director of Therapy Research and Analysis 9.8 About GlobalData 9.9 Disclaimer
List of Tables
Table 1: Classification and Criteria of Bipolar Disorder According to DSM-V and ICD-10-CM Table 2: DSM-V Bipolar Disorder Specifiers Table 3: Symptoms of Manic, Hypomanic, and Major Depressive Episodes in Bipolar Disorder Table 4: Screening Tools Used for Bipolar Disorder Table 5: Treatment Guidelines for Bipolar Disorder Table 6: Most Prescribed Drugs for Bipolar Disorder by Episode Type in the Global Markets, 2014 Table 7: Country Profile - Canada Table 8: Leading Treatments for Bipolar Disorder, 2015 Table 9: Product Profile - Lithium Table 10: Lithium SWOT Analysis, 2015 Table 11: Global Sales Forecasts ($m) for Lithium, 2014-2024 Table 12: Product Profile - Carbamazepine Table 13: Efficacy Results for Equetro in Bipolar Mania Trials Table 14: Adverse Events at =5% Incidence in Bipolar Mania Trials of Equetro Table 15: Carbamazepine SWOT Analysis, 2015 Table 16: Global Sales Forecasts ($m) for Carbamazepine, 2014-2024 Table 17: Product Profile - Lamotrigine Table 18: Adverse Events at =5% Incidence in Bipolar Maintenance Trials of Lamictal Table 19: Lamotrigine SWOT Analysis, 2015 Table 20: Global Sales Forecasts ($m) for Lamotrigine, 2014-2024 Table 21: Product Profile - Valproate Table 22: Efficacy Results for Depakote in Bipolar Mania Trials Table 23: Adverse Events at =5% Incidence in Bipolar Mania Trials of Depakote Table 24: Valproate SWOT Analysis, 2015 Table 25: Global Sales Forecasts ($m) for Valproate, 2014-2024 Table 26: Typical Antipsychotics by Chemical Class Table 27: Typical antipsychotics SWOT Analysis, 2015 Table 28: Global Sales Forecasts ($m) for the Typical Antipsychotics, 2014-2024 Table 29: Product Profile - Adasuve Table 30: Efficacy Results for Adasuve in Agitation Trial of Bipolar I Disorder Patients Table 31: Decrease in FEV1 in Pulmonary Safety Trials of Adasuve Table 32: Adasuve SWOT Analysis, 2015 Table 33: Global Sales Forecasts ($m) for Adasuve, 2014-2024 Table 34: Product Profile - Abilify Table 35: Efficacy Results for Abilify in Bipolar Mania Trials Table 36: Efficacy Results for Abilify in Agitation Trials Table 37: Adverse Events at =2% Incidence in Bipolar I Disorder and Schizophrenia Trials of Abilify Table 38: Abilify SWOT Analysis, 2015 Table 39: Global Sales Forecasts ($m) for Abilify, 2014-2024 Table 40: Product Profile - Geodon Table 41: Adverse Events at =2% Incidence in Bipolar Mania Trials of Geodon Table 42: Geodon SWOT Analysis, 2015 Table 43: Global Sales Forecasts ($m) for Geodon, 2014-2024 Table 44: Product Profile - Latuda Table 45: Efficacy Results for Latuda in Bipolar Depression Trials Table 46: Adverse Events at =2% Incidence in Bipolar Depression Trials of Latuda Table 47: Latuda SWOT Analysis, 2015 Table 48: Global Sales Forecasts ($m) for Latuda, 2014-2024 Table 49: Product Profile - Risperdal Table 50: Efficacy Results for Risperdal in Trial of Manic and Mixed Bipolar Episodes Table 51: Adverse Events at =2% Incidence in Bipolar Mania Trials of Risperdal Table 52: Adverse Events at =2% Incidence in Bipolar Maintenance Trials of Risperdal Consta Table 53: Risperdal SWOT Analysis, 2015 Table 54: Global Sales Forecasts ($m) for Risperdal, 2014-2024 Table 55: Global Sales Forecasts ($m) for Risperdal Consta, 2014-2024 Table 56: Product Profile - Saphris Table 57: Efficacy Results for Saphris in Bipolar Mania Studies Table 58: Adverse Events at =2% Incidence in Bipolar I Disorder Trials of Saphris Table 59: Saphris SWOT Analysis, 2015 Table 60: Global Sales Forecasts ($m) for Saphris, 2014-2024 Table 61: Product Profile - Seroquel Table 62: Efficacy Results for Seroquel in Bipolar Mania Studies Table 63: Efficacy Results for Seroquel in Bipolar Depression Trials Table 64: Efficacy Results for Seroquel XR in Bipolar Disorder Trials Table 65: Adverse Events at =2% Incidence in Bipolar Disorder Trials of Seroquel Table 66: Adverse Events at =2% Incidence in Bipolar Disorder Trials of Seroquel XR Table 67: Seroquel SWOT Analysis, 2015 Table 68: Global Sales Forecasts ($m) for Seroquel, 2014-2024 Table 69: Global Sales Forecasts ($m) for Seroquel XR, 2014-2024 Table 70: Product Profile - Symbyax Table 71: Efficacy Results for Symbyax in Bipolar Depression Trials Table 72: Adverse Events at =2% Incidence in Bipolar Depression and Treatment-Resistant Depression Trials of Symbyax Table 73: Symbyax SWOT Analysis, 2015 Table 74: Global Sales Forecasts ($m) for Symbyax, 2014-2024 Table 75: Product Profile - Vraylar Table 76: Vraylar SWOT Analysis, 2015 Table 77: Global Sales Forecast ($) for Vraylar, 2014-2024 Table 78: Product Profile - Zyprexa Table 79: Adverse Events at =2% Incidence in Bipolar Mania Trials of Zyprexa Table 80: Adverse Events at =2% Incidence in Trials of Zyprexa IntraMuscular in Agitation Associated with Schizophrenia or Bipolar I Mania Table 81: Zyprexa SWOT Analysis, 2015 Table 82: Global Sales Forecasts ($m) for Zyprexa, 2014-2024 Table 83: Product Information for the Most Commonly Prescribed "Other Antipsychotics" Table 84: International Society for Bipolar Disorders Clinical Recommendations for Antidepressant Use in Bipolar Disorder Table 85: Antidepressants SWOT Analysis, 2015 Table 86: Global Sales Forecasts ($m) for the Antidepressants, 2014-2024 Table 87: Summary of Minor Therapeutic Classes, 2015 Table 88: Unmet Need and Opportunity in Bipolar Disorder Table 89: Product Profile - Abilify Maintena Table 90: Adverse Events at =2% Incidence in a Schizophrenia Trial of Abilify Maintena Table 91: Abilify Maintena SWOT Analysis, 2015 Table 92: Global Sales Forecast ($) for Abilify Maintena, 2014-2024 Table 93: Product Profile - ITI-007 Table 94: Efficacy Results for ITI-007 in a Phase II Schizophrenia Trial Table 95: Key Safety Data From a Phase II in a Schizophrenia Trial of ITI-007 Table 96: ITI-007 SWOT Analysis, 2015 Table 97: Potential Off-label Bipolar Disorder Late-Stage Pipeline Drugs Table 98: Drugs in Development, 2015 Table 99: Sales Forecasts ($m) for Bipolar Disorder in Canada, 2014-2024 Table 100: Key Events Impacting Sales for Bipolar Disorder in Canada, 2014-2024 Table 101: Bipolar Disorder Market in Canada - Drivers and Barriers, 2014-2024 Table 102: Key Launch Dates Table 103: Key Patent Expiries Table 104: High-Prescribing Physicians (Non-KOLs) Surveyed, By Country
List of Figures
Figure 1: The Etiology and Pathophysiology of Bipolar Disorders Figure 2: The Effects of Lithium on Neurotransmission Figure 3: The Effects of Lithium on Second Messenger Pathways Figure 4: Bipolar Disorder Therapeutics - Class of Therapy, 2016 Figure 5: Bipolar Disorder - Phase II-III Pipeline, 2015 Figure 6: Clinical and Commercial Positioning of Abilify Maintena Figure 7: Clinical and Commercial Positioning of ITI-007 Figure 8: Sales for Bipolar Disorder in Canada by Drug Class, 2014-2024
Global embedded system market is projected to be valued at USD 214.39 billion by 2020, as per a new research report by Radiant Insights, Inc. Rising demand from end-use industries such as automotive and healthcare coupled with emergence of Internet oRead More...
Global automotive ECU market is projected to be valued at USD 45.98 billion by 2020, as per a new research report by Radiant Insights, Inc. Rising use in infotainment systems coupled with high deployment in electric vehicles applications is expectedRead More...
Global thermoplastic polyurethane (TPU) films market size is likely to be valued at USD 724.6 million by 2020; as per a new research report by Radiant Insights, Inc. Increase in lightweight plastics demand in order to achieve vehicle fuel efficiencyRead More...
Global compressed air treatment equipment market is projected to reach USD 8.59 billion by 2020, as per a new research report by Radiant Insights, Inc. Growing implementation of this equipment in various industry sectors such as healthcare & pharmaceRead More...
Global 3D scanning market is expected to be valued at USD 4,900.7 million by 2020, as per a new research report by Radiant Insights, Inc. Increasing need for speedy and precise results with high efficiency is anticipated to drive the industry. 3DRead More...
Get your queries resolved from an industry expert. Request for a free product review before report purchase.
Toll Free: 1-888-928-9744
Email: [email protected]
Speak to the report author to design an exclusive study to serve your research needs.
A testimonial for service excellence represented in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.